Pathophysiology of Bisphosphonates associated Osteonecrosis of the Jaw (R21) | Apply Online

Opportunity Summary:

This funding opportunity (PA-06-501) is an NIH Exploratory/Developmental Grant (R21) announcement focused on understanding bisphosphonate-associated osteonecrosis of the jaw (ONJ), a serious oral complication that can occur in some patients receiving bisphosphonate therapy. The National Institute of Dental and Craniofacial Research (NIDCR) is leading the effort in partnership with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Cancer Institute (NCI). The central goal is to support early-stage, hypothesis-generating basic and translational research that pinpoints the biological mechanisms behind impaired jawbone healing and the progression to ONJ, with an emphasis on why the jaw appears uniquely vulnerable compared with other skeletal sites.

The scientific scope is tightly centered on oral bone biology: applicants are expected to investigate oral bone homeostasis, wound healing, repair capacity, and related pathophysiology in the presence or absence of bisphosphonates. The intent is not to broadly study bisphosphonates and skeletal biology in general; projects that look at general bone quality or skeletal effects are considered outside the target area unless they directly include and analyze oral bones. Similarly, studies may examine related physiological processes, such as angiogenesis, immune responses, infection or inflammation, and soft tissue contributions, but only when those processes are explicitly framed as mechanisms that could disrupt oral bone maintenance and healing in a way that promotes ONJ. In other words, the jaw-specific environment and its healing dynamics are the priority, and the proposed work needs to connect mechanistic dots that plausibly explain the development of ONJ in the oral cavity.

The FOA also draws clear boundaries around what is considered responsive. Epidemiological studies are explicitly non-responsive, meaning population-level association studies or purely observational incidence/risk-factor analyses are not what this R21 is meant to fund. Bisphosphonate pharmacology projects are also generally non-responsive unless they specifically test whether genetic variation changes bisphosphonate pharmacokinetics or pharmacodynamics in a way that could contribute to ONJ risk. That carve-out signals NIH interest in mechanistic, biologically grounded explanations for patient-to-patient differences, rather than descriptive pharmacology alone. Overall, NIH is pushing applicants toward mechanistic models and translational approaches that can explain causality and identify actionable biological pathways rather than just correlations.

As an R21 mechanism, the opportunity is designed for exploratory, developmental work where preliminary data may be limited and where the aim is to open new lines of inquiry or test innovative concepts. The award ceiling listed is $200,000, and cost sharing or matching is not required. The announcement notes that awards depend on available funds and on receiving a sufficient number of high-quality applications, which is standard language but also a reminder that this is a competitive program.

This R21 runs in parallel with two companion announcements that share the same scientific scope but use different grant mechanisms: an R01 (PA-06-500) for larger, more mature projects and an R03 (PA-06-502) for small research grants. Together, these parallel FOAs create multiple entry points for teams at different stages of readiness, from smaller pilot studies (R03) to exploratory innovation (R21) to fully powered, longer-term projects (R01), all aimed at the same overarching question of ONJ pathophysiology.

Eligibility is broad and includes a wide range of domestic organizations, such as universities (public and private), nonprofits (including 501(c)(3) and non-501(c)(3) entities), for-profit organizations (including small businesses), and multiple levels of government (state, county, city/township, special districts), along with tribal governments and tribal organizations. Foreign institutions are eligible, and eligible federal agencies may apply as well. Faith-based and community-based organizations are also allowed, and applicants may submit more than one application as long as each one is scientifically distinct, which is helpful for groups pursuing multiple mechanistic angles.

In terms of timing and administrative details, the opportunity was posted July 31, 2006, with multiple receipt dates (rather than a single deadline), and it ultimately closed in 2009 (with an archive date of October 7, 2009). The activity area is health-related research and it is associated with CFDA program areas spanning oral diseases and disorders research (93.121), cancer treatment research (93.395), and arthritis/musculoskeletal/skin diseases research (93.846). The full announcement link provided is hosted on the NIH Grants Guide, and NIH’s Office of Extramural Research (OER) is listed as the contact point for technical access issues.

Taken as a whole, PA-06-501 is essentially a targeted call for innovative, mechanism-driven projects that can explain how bisphosphonates, in the context of the oral environment, may contribute to breakdowns in jawbone healing that culminate in ONJ. The emphasis on oral bone-specific analyses, the exclusion of epidemiology, and the narrow allowance for pharmacology only when tied to genetic variation all reinforce that the program is looking for biologically precise, experimentally grounded insights that can move the field toward prevention and better clinical management of this complication.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Oral Health Research Education Grants (R25)

Previous opportunity: Pathophysiology of Bisphosphonates associated Osteonecrosis of the Jaw (R03)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 06 501

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 06 501) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 501", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.